ALSO NOTED: AstraZeneca to sue Ranbaxy; Neurochem begins enrolling for Alzheimer's trial; and much more...

> Jazz Pharmaceuticals announced that Xyrem (sodium oxybate) oral solution has been approved for marketing by the FDA to treat excessive daytime sleepiness in patients with narcolepsy. Release

> A new study of 10,000 patients found that patients taking either low-molecular-weight heparin (enoxaparin) or unfractionated heparin were equally effective in reducing death or heart attack. Report

> AstraZeneca says it will sue Ranbaxy over its challenge to the patent for the ulcer drug Nexium. Report

> Canada's Neurochem has begun enrolling patients for a Phase III trial of its Alzheimer's therapy Alzhemed. Report

> Tripos announced that its file enrichment collaboration with Pfizer will conclude in December 2005. Release

And Finally… Economist Robert Samuelson says that the new Medicare drug benefit is a calamity as government policy. Column